Pygeum is an African plum bark extract with notable evidence for nocturia, along with a sustainability issue that deserves more attention.
By Dr. Marcus Reed, MD · Last Updated: July 23, 2026
What the evidence says: Pygeum africanum, now commonly called Prunus africana, is an extract made from African plum tree bark. It has been prescribed as a registered medicine in France and Italy since the 1970s. A meta-analysis of 18 randomized trials found men taking it were more than twice as likely to report improved urinary symptoms, with nocturia reduced by roughly 19%, residual urine volume by 24%, and peak urine flow increased by 23% versus placebo. Typical dosing is 100-200 mg daily standardized to 14% triterpenes.
Budget prostate formulas often leave out pygeum, while broader formulas are more likely to include it. It has an impressive meta-analysis behind it, its strongest evidence relates to the symptom men care about most — waking at night — and it carries a sustainability story that almost no supplement page mentions. All three are worth knowing.
Prunus africana, historically classified as Pygeum africanum, is an evergreen tree native to the montane forests of tropical Africa, growing across Cameroon, Kenya, Madagascar, Uganda and neighboring regions. It can reach 40 meters and is sometimes called the African plum or African cherry.
The medicinal part is the bark. Traditional healers across sub-Saharan Africa used bark preparations for urinary complaints long before any European involvement. In the 1960s French researchers investigated it, a standardized lipophilic bark extract was developed, and it was subsequently registered as a pharmaceutical product in France and Italy where it has been prescribed for BPH ever since.
The extract contains three groups of lipid-soluble constituents: phytosterols (principally beta-sitosterol), pentacyclic triterpenoids including ursolic and oleanolic acids, and ferulic esters of fatty alcohols, notably n-docosanol. Standardization is normally to 12-14% total sterols and triterpenes.
Pygeum's mechanism differs meaningfully from saw palmetto's, which is exactly why the two are complementary rather than redundant.
The pentacyclic triterpenoids act as anti-edema agents, and the phytosterol fraction reduces the elevated prostaglandin levels found in men with BPH. Less prostaglandin activity means less inflammation and less tissue swelling, which relieves pressure on the urethra without needing to change the gland's cell count.
Pygeum extract inhibits fibroblast growth factors including bFGF and EGF, implicated in the fibrous and stromal proliferation component of prostate enlargement. This is a distinct target from the androgen pathway that saw palmetto and beta-sitosterol act on, and it addresses a part of BPH that hormonal ingredients largely do not.
Some research indicates pygeum improves bladder contractility and elasticity independently of any prostate effect. Since long-standing obstruction causes secondary bladder wall changes that persist even after obstruction is relieved, an ingredient acting on the bladder itself is useful — and probably explains why its nocturia evidence is comparatively strong.
Laboratory work has found ethanolic pygeum extracts inhibit growth of prostate cell lines, induce apoptosis and alter cell kinetics, with investigators concluding a significant regulatory role in vitro and in animal models (see the clinical meta-analysis for the human evidence). This is preclinical mechanism research, not a claim that pygeum treats or prevents cancer in humans, and should not be read that way.
Pygeum's headline evidence is a systematic review and quantitative meta-analysis published in the American Journal of Medicine, pooling 18 randomized controlled trials involving over 1,500 men. Seventeen of the eighteen were double-blinded, with a mean study duration of 64 days (PMID 11099686).
The reviewers themselves were careful about the quality of the underlying evidence. Many studies did not report results in a form permitting meta-analysis. Only one of the eighteen reported a method of treatment allocation concealment — a significant methodological gap. The studies were relatively short, averaging around two months, and mostly conducted decades ago under different standards. Modern large-scale placebo-controlled trials of pygeum are notably scarce.
So the fair reading is: consistent and reasonably sized effects across a substantial number of trials, tempered by methodological limitations typical of the era. That is a stronger evidence base than most supplement ingredients have, and weaker than a modern pharmaceutical approval package.
Standard dosing is 100 mg daily of extract standardized to approximately 14% triterpenes and 0.5% n-docosanol, though 50 mg twice daily and 200 mg daily have both been used. Randomized comparison of once-daily against twice-daily dosing found both effective with a long-term open-label extension, which makes once-daily practical for most men.
Pygeum appears as one of the named ingredients in Prostate 911 rather than inside the proprietary blend, which is the right call given its evidence. As with the other lead botanicals, the label does not state a standardization percentage — so the triterpene content, which is the number that determines whether it resembles the studied extract, cannot be verified from the panel.
This deserves its own section because it is a genuine issue and most supplement content omits it entirely.
Harvesting pygeum requires stripping bark from the tree. Done properly — removing bark from opposite quarters of the trunk and allowing regeneration — the tree survives and can be re-harvested years later. Done improperly, through complete ring-barking, the tree dies.
Commercial demand from Europe and North America drove exactly the improper kind of harvesting across parts of Africa for decades. Prunus africana was consequently listed under CITES Appendix II, meaning international trade is regulated and requires permits confirming sustainable sourcing. Some exporting countries have faced trade suspensions over unsustainable practices.
The practical implication for buyers: sustainably sourced pygeum exists, from managed plantations and certified wild-harvest programmes, but it costs more. Very cheap pygeum is a reasonable prompt to ask where it came from. Some manufacturers state their sourcing; most do not. If this matters to you, contacting the manufacturer directly is the only reliable route — and it is a legitimate reason some formulas use pygeum sparingly.
Pygeum's tolerability in trials was good, with adverse effect rates comparable to placebo across the meta-analyzed studies.
One thing distinguishes pygeum from almost every other ingredient in the prostate aisle: in several countries it is not a supplement at all.
Standardized pygeum bark extract has been registered and prescribed as a pharmaceutical medicine in France and Italy for the management of BPH since the 1970s, and has been available as a registered product in other European and African markets. In the United States and United Kingdom it is sold as a dietary supplement under entirely different regulatory requirements.
This matters for interpreting the evidence. Much of the trial literature was generated in a European pharmaceutical context, testing a specific standardized preparation under medicine-development conditions, rather than testing whatever happened to be in a supplement bottle. That is part of why pygeum's trial record is more internally consistent than saw palmetto's — the material being tested was itself more consistent.
It also means a European registered product and an American supplement labeled "pygeum" may differ considerably. When a study reports benefit at 100 mg, it reports benefit for a defined extract, not for 100 mg of any bark preparation. The standardization figure on the label is the only bridge between the two, which is why its absence is significant.
Pygeum's distinctive value is its evidence profile on nocturia specifically. For a man whose main complaint is waking two or three times a night, that is the most relevant outcome measure available, and the meta-analysis addresses it directly with a 19% reduction figure.
It works best as part of a combination rather than alone, since its mechanism sits alongside rather than overlapping the androgen-pathway ingredients. A formula containing beta-sitosterol, saw palmetto, nettle and pygeum covers hormonal, SHBG, inflammatory and growth-factor pathways — which is coherent design rather than ingredient-stuffing.
Pair it with the behavioral measures that address nocturia directly: fluid timing, evening alcohol reduction, early-evening leg elevation and double voiding. Our nocturia guide covers these in detail, and supplements plus behavior consistently outperform either alone.
And keep the limits in view. Two months of pygeum will not resolve severe obstruction, and any sudden change in urinary pattern, blood in the urine, or inability to urinate needs a doctor rather than a capsule.
Pygeum is rarely used alone, and the standard combinations have logic behind them.
The most common pairing and a complementary one. Saw palmetto works predominantly on the androgen pathway; pygeum on inflammation, growth factors and bladder function. Where one addresses the hormonal driver of tissue growth, the other addresses the swelling and bladder dysfunction that translate that growth into symptoms. Combination products have been standard in European practice for decades.
Partly overlapping, since pygeum itself contains phytosterols including beta-sitosterol. Adding a separate plant sterol component pushes the total sterol dose toward the 60-130 mg range shown effective in trials, which pygeum alone at 100 mg would not reach. Reasonable design rather than duplication.
A traditional European combination with its own trial history — one randomized placebo-controlled study specifically evaluated a pygeum and nettle combination for BPH. The two work on different pathways again, pygeum on inflammation and nettle on SHBG and aromatase.
This requires a conversation, not a solo decision. Men already taking an alpha-blocker or 5-alpha-reductase inhibitor should not simply add botanicals — particularly given pygeum's status as a registered medicine in some jurisdictions and the PSA-interpretation issue. There is no reason to assume harm, but every reason for your prescriber to know the full picture.
For men not yet on prescription treatment, a combination formula containing pygeum alongside saw palmetto, beta-sitosterol and nettle represents a coherent first step for mild-to-moderate symptoms — provided it is treated as a first step, with a twelve-week evaluation window and a plan to escalate, rather than an indefinite substitute for finding out what is actually going on.
Key takeaway: Pygeum has the strongest specific evidence of any natural ingredient for nocturia — a 19% reduction across an 18-trial meta-analysis — and works through anti-inflammatory and growth-factor pathways rather than the androgen route, making it complementary to saw palmetto. Look for 100-200 mg standardized to 14% triterpenes.
Saw palmetto, beta-sitosterol, pygeum, nettle and pumpkin seed in one daily formula. 90-day money-back guarantee.
Order from Official Website